About ISCaM

Mission statement 
The mission of ISCaM (ex ISPDC, International Society for Proton Dynamics in Cancer) is to improve communication and to foster collaborative activities and research programs between European and non European scientists engaged in acidity, proton dynamics, metabolism and microenvironment in cancer research. ISCaM can consolidate, co-ordinate and facilitate International collaboration, facilitate translation of research to clinical development, and fundraise for Networking activities, scientific programs and projects, scientists mobility, young scientists grants and carrier programs
 
Aim of ISCaM:
To advocate and effectively promote our approach to cancer therapy in the scientific community, social community, Funding Agencies, Governments, and stimulate translation into clinical applications. To create a critical mass of scientists engaged in research activities on Metabolism in Cancer. To gain visibility at National, European and International level. To duly raise the necessary awareness of both the scientific community and society. To attract resources to finance and conduct research in the field of metabolism in cancer. To be recognized as an important counterpart for the European Commission, funding agencies and Industry. To represent the main scientific stakeholder in the field.
 
 

Board members

Pierre Sonveaux

Role: 
President

Prof. Pierre Sonveaux is a F.R.S.-FNRS Research Associate at Université catholique de Louvain, IREC Institute, Pole of Pharmacology, Brussels, BE. He leads a team active in translational researches focused on tumor metabolism and its influences on angiogenesis and metastatic progression, with a particular focus on lactate and monocarboxylate (MCT) transporters. Works are supported by ERC starting grant TUMETABO. 

Angelo De Milito

Role: 
Secretary

Angelo De Milito is an Associate Professor in Experimental Oncology at the Department of Oncology-Pathology, Karolinska Institute (Sweden). His research is focused on identifying mechanisms modulating the ability of cancer cells to adapt to acidic stress (including autophagy) and use such mechanisms as therapeutic targets to selectively and specifically kill cancer cells.

Paolo Porporato

Role: 
Treasurer

Paolo Porporato is a tenure-track research associate at the Department of Molecular Biotechnologies  at the University of Torino. Following a postdoctoral experience at Université catholique de Louvain​ in defining the metabolic determinants of tumor metastasis, he is currently  working on defining the impact of metabolism on the progression of cancer cachexia.​ 

Angela M. Otto

Role: 
Board member

Senior scientist and lecturer at the Institute of Medical Engineering (IMETUM), Technical University of Munich, Germany.  As a cell biologist and biochemist she has worked on the effects of anticancer agents in breast cancer cells and is now focussing on metabolic activities under variable conditions representing a tumor microenvironment, including acidic pH. Since this topic is of particular relevance in metabolic imaging of cancer, she is cooperating with partners at General Electric Global Research-Europe and at the Department of Nuclear Medicine, University Hospital Rechts der Isar.

Nicola Baldini

Role: 
Board member

Professor in Orthopaedic Surgery, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy. He is also a staff surgeon, Orthopaedic Oncology, Clinica Ortopedica e Traumatologica I, and Head of the Orthopaedic Pathophysiology and Regenerative Medicine Lab, Istituto Ortopedico Rizzoli, Italy. Member of the Faculty of the PhD Program in Biomedical Sciences, University of Bologna.

Silvia Pastorekova

Role: 
Board member

  Prof. Silvia Pastorekova, DSc., is heading the Department of molecular medicine at the Institute of Virology, Slovak Academy of Sciences in Bratislava, Slovakia. She principally contributed to identification, molecular and functional characterization of carbonic anhydrase IX, a component of pH-regulating machinery of tumor cells, and a marker of hypoxia with prognostic and predictive value.

Robert J. Gillies

Role: 
Board member

Chair of the Department of Cancer Imaging and Metabolism, at the MOFFITT Cancer Center. Vice-chair of Radiology, and co-leader of the Experimental Therapeutics Program at the Moffitt Cancer Center. Extramurally, President of the Society of Molecular Imaging, a member of the Cell and Molecular Imaging Probes (CMIP) study section at NIH. His research is focused on functional and molecular imaging of cancer , and on cancer metabolism and microenvronment, and is divided into three related programs, all supported by NIH/NCI grants and all with pre-clinical and clinical components.

Stine Falsig Pedersen

Role: 
Board member

Professor at University of Copenhagen, Department of Cell and Developmental Biology. Main research interests of Prof. Pedersen are regulation, physiology, and pathophysiology of pH regulatory ion transport proteins, in particular with respect to their roles in cell motility and cancer development, and in structure-function studies of the Na+/H+ exchanger NHE1 and the Na+,HCO3-cotransporter NBCn.

Claudiu Supuran

Role: 
Board member

Professor at the University of Florence. The interest of Prof. Claudiu Supuran in Carbonic Anhydrase research dates back to 1987. Since then, the group of Prof. Supuran was involved in several research projects on CA inhibitors and activators, financed either by the European Union or from private drug companies. Prof. Supuran realised many important discoveries related  to this field, and has achieved international recognition,  

Sofia Avnet

Role: 
Board member

Sofia Avnet is a staff Biotechnologist at Orthopaedic Pathophysiology and Regenerative Medicine Lab, Istituto Ortopedico Rizzoli, Italy. Avnet research activity is mainly focused on bone cell biology and bone tumors. She has recently gained interest in the role of the V-ATPase and of proton secretion in the tumor invasiveness and chemoresistance in Ewing’s sarcoma and osteosarcoma, and in the role of different ion/proton transporters in bone metastases. More recently, she also has been focused on the metabolic reprogramming during the stroma-tumor interactions.